REPARE THERAPEUTICS INC (RPTX) Stock Fundamental Analysis

NASDAQ:RPTX • US7602731025

2.65 USD
+0.02 (+0.76%)
At close: Jan 27, 2026
2.65 USD
0 (0%)
After Hours: 1/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

RPTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While RPTX has a great health rating, there are worries on its profitability. RPTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RPTX has reported negative net income.
  • RPTX had a negative operating cash flow in the past year.
  • RPTX had negative earnings in each of the past 5 years.
  • In the past 5 years RPTX reported 4 times negative operating cash flow.
RPTX Yearly Net Income VS EBIT VS OCF VS FCFRPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of RPTX (-56.96%) is comparable to the rest of the industry.
  • RPTX's Return On Equity of -62.71% is fine compared to the rest of the industry. RPTX outperforms 60.38% of its industry peers.
Industry RankSector Rank
ROA -56.96%
ROE -62.71%
ROIC N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
RPTX Yearly ROA, ROE, ROICRPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPTX Yearly Profit, Operating, Gross MarginsRPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RPTX has more shares outstanding
  • Compared to 5 years ago, RPTX has more shares outstanding
  • RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RPTX Yearly Shares OutstandingRPTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPTX Yearly Total Debt VS Total AssetsRPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • RPTX has an Altman-Z score of -0.11. This is a bad value and indicates that RPTX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.11, RPTX is in the better half of the industry, outperforming 60.19% of the companies in the same industry.
  • RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.11
ROIC/WACCN/A
WACC8.03%
RPTX Yearly LT Debt VS Equity VS FCFRPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • RPTX has a Current Ratio of 10.71. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
  • RPTX has a Current ratio of 10.71. This is amongst the best in the industry. RPTX outperforms 84.38% of its industry peers.
  • RPTX has a Quick Ratio of 10.71. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RPTX (10.71) is better than 84.38% of its industry peers.
Industry RankSector Rank
Current Ratio 10.71
Quick Ratio 10.71
RPTX Yearly Current Assets VS Current LiabilitesRPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • RPTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.00%, which is quite good.
  • RPTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.16%.
  • Measured over the past years, RPTX shows a very strong growth in Revenue. The Revenue has been growing by 91.62% on average per year.
EPS 1Y (TTM)15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.94%
Revenue 1Y (TTM)-82.16%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, RPTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.74% on average per year.
  • Based on estimates for the next years, RPTX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-7.61%
EPS Next 2Y27.58%
EPS Next 3Y19.21%
EPS Next 5Y16.74%
Revenue Next Year-99.47%
Revenue Next 2Y-65.57%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RPTX Yearly Revenue VS EstimatesRPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
RPTX Yearly EPS VS EstimatesRPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • RPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPTX Price Earnings VS Forward Price EarningsRPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPTX Per share dataRPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • RPTX's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.58%
EPS Next 3Y19.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RPTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REPARE THERAPEUTICS INC

NASDAQ:RPTX (1/27/2026, 8:00:02 PM)

After market: 2.65 0 (0%)

2.65

+0.02 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners49.86%
Inst Owner Change-7.08%
Ins Owners0.35%
Ins Owner Change-1481.28%
Market Cap113.92M
Revenue(TTM)11.87M
Net Income(TTM)-72.20M
Analysts80
Price Target3.06 (15.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)78.35%
Min EPS beat(2)22.9%
Max EPS beat(2)133.81%
EPS beat(4)4
Avg EPS beat(4)44.79%
Min EPS beat(4)5.7%
Max EPS beat(4)133.81%
EPS beat(8)7
Avg EPS beat(8)235.55%
EPS beat(12)9
Avg EPS beat(12)166.28%
EPS beat(16)12
Avg EPS beat(16)143.18%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-83.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-49.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-96.08%
Revenue NY rev (3m)-97.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.6
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0.28
BVpS2.68
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.96%
ROE -62.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.71
Quick Ratio 10.71
Altman-Z -0.11
F-Score3
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)43.21%
Cap/Depr(5y)98.7%
Cap/Sales(3y)1.42%
Cap/Sales(5y)453.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.94%
EPS Next Y-7.61%
EPS Next 2Y27.58%
EPS Next 3Y19.21%
EPS Next 5Y16.74%
Revenue 1Y (TTM)-82.16%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-99.47%
Revenue Next 2Y-65.57%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y13.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.47%
OCF growth 3YN/A
OCF growth 5YN/A

REPARE THERAPEUTICS INC / RPTX FAQ

What is the ChartMill fundamental rating of REPARE THERAPEUTICS INC (RPTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RPTX.


Can you provide the valuation status for REPARE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to REPARE THERAPEUTICS INC (RPTX). This can be considered as Overvalued.


What is the profitability of RPTX stock?

REPARE THERAPEUTICS INC (RPTX) has a profitability rating of 1 / 10.


What is the expected EPS growth for REPARE THERAPEUTICS INC (RPTX) stock?

The Earnings per Share (EPS) of REPARE THERAPEUTICS INC (RPTX) is expected to decline by -7.61% in the next year.